Investor FAQs
|
|
- Corporate information |
|
- Equity shares information |
|
- Investor calendar |
- Investor contact information
|
Corporate Information
|
| 1. What is Biocon's area of operations? |
Biocon is a global provider of innovative biopharmaceutical products and research services that span the entire drug value chain: pre-clinical discovery to clinical development to commercialization. The Biocon group of companies consists of Biocon Limited, the flagship company, its six subsidiaries – Syngene, Clinigene, Biocon Research Limited, Biocon Biopharmaceuticals, Biocon SND.BHD and Biocon SA – and one joint venture company Neobiocon.
|
|
Biopharmaceuticals
|
The principal areas of operation include –
Biopharmaceuticals – Biocon’s pharmaceuticals business comprises the development and manufacture of active pharmaceutical ingredients and finished dosages. The primary focus is on products that involve fermentation and or synthetic conversion. Biocon has brought to the market a considerable portfolio of biopharmaceuticals, led by statins. The commercialization of insulin, immunosuppressants and a range of biogenerics demonstrates the company’s highly advanced process development and manufacturing expertise.
|
| Custom & Clinical Research Services |
Biocon provides contract research services to overseas and domestic customers in the following areas:
|
|
- Molecular Biology |
|
- Biologics |
|
- Synthetic Chemistry |
|
- Bioinformatics |
- Clinical research on well-defined and
characterised patients suffering from chronic diseases such as diabetes,
osteoporosis, asthma, etc.
|
| 2. What is the address of Biocon’s registered office? |
|
Biocon has its corporate and registered office at Bangalore.
|
BIOCON LIMITED
20th KM, Hosur Road
Electronic City PO
Bangalore - 560 100
Ph +91 80 2808 2808
Fax +91 80 2852 3423
|
|
3. Where and in which year was Biocon incorporated?
|
Biocon was incorporated on November 29, 1978 in Bangalore, India.
|
|
4. What is the total employee strength at Biocon Group?
|
Team Biocon comprises of 6000+ employees (as on Dec 31, 2011) in various fields, with a strong scientist portfolio.
|
| 5. What is Biocon’s consolidated revenue and profits for the recently concluded period and for the last 12 months? |
| Rupees Crores |
FY11 |
9MFY12 |
| Revenues |
2814 |
1511 |
Profit After Tax |
368 |
241 |
|
6. Where can I obtain information on Biocon’s financial results? |
To obtain the financial results of the company, please refer to our website under the Investor Relations section. Alternatively, the same is also available at the website of National Stock Exchange (NSE) and Mumbai Stock Exchange (BSE).
|
The results of the company are also published in leading Business Dailies.
|
| 7. Who are the members on Biocon’s Board of Directors? |
|
Biocons' Board consists of:
|
|
Ms. Kiran Mazumdar-Shaw, Chairman and Managing Director
|
|
Mr. John Shaw
|
|
Dr. Neville Bain
|
|
Prof Charles L Cooney
|
|
Mr. Suresh Talwar
|
|
Prof Ravi Mazumdar
|
|
Dr. Bala Manian
|
| Mr. Russell Walls
|
Prof Catherine Rosenberg, Alternate Director to Ravi Mazumdar
|
Mr. Peter Bains
|
Equity Shares Information
|
|
1. When did Biocon have its Initial Public Offer (IPO) ?
|
In March 2004, Biocon went public with an IPO of 10,000,000 fresh equity shares of Rs. 5 each at a price of Rs. 315 per share.
|
|
2. On which stock exchanges are Biocon shares listed and what are the codes?
|
| Name of Exchange |
Code |
| National Stock Exchange, Mumbai (NSE) |
BIOCON |
| Mumbai Stock Exchange, (BSE) |
532523 |
|
3. Where can I obtain details on Biocon’s stockholders? |
Details of shareholding pattern of the company as at Dec 31, 2011 is available on our website in the Investor Relations Section. The same is also available on the NSE and BSE websites.
|
|
4. Does Biocon pay dividends?
|
|
The Company has been consistently paying dividend since 2004. For the fiscal year 2011, the Company has declared an interim dividend of 30% (i.e., Rs 1.50 per share) and the board has recommended a final dividend of 60% (i.e., Rs. 3.00 per share).
|
|
5. What is the percentage breakdown of shareholders?
|
|
The shareholding pattern of Biocon shares as at Dec 31, 2011 |
| Employees and ESOP Trust |
5% |
| Promoters |
61% |
| Public, Institutional and Others |
34% |
|
Investor Calendar
|
|
1. What is the date of release of financial results?
|
|
The tentative calendar for the financial results for the fiscal year 2012 is as follows: |
| Q1 FY 2012 |
July 21, 2011 |
| Q2 FY 2012 |
October 19, 2011 |
| Q3 FY 2012 |
January 24, 2012 |
| Q4 FY 2012 |
Apr 26, 2012 |
|
2. When is the next AGM? |
The Annual General Meeting (AGM) of the Company for the year 2011-12 is proposed to be held on July 26, 2012.
|
|
3. Does the Company have any quiet periods?
|
|
Yes. Biocon follows quiet periods prior to its quarterly results ie. starting at the end of the last quarter and ending on the day of announcement of earnings. During this time, the Company or any of its officials will not discuss earnings expectations with any external parties. Based on tentative dates of earnings release in fiscal 2012, the tentative quiet periods would be as follows: |
| Quarter ending |
Earnings release date |
Quiet period |
| June 30, 2011 |
July 21, 2011 |
Jul 1, 2011 to Jul 21, 2011 |
| Sep 30, 2011 |
October 19, 2011 |
Oct 1, 2011 to Oct 19, 2011 |
| Dec 31, 2011 |
Jan 24, 2012 |
Jan 1, 2012 to Jan 24, 2012 |
| Mar 31, 2012 |
Apr 26, 2012 |
Apr 1, 2012 to Apr 26, 2012 |
|
Investor Contact Information
|
|
Investor Contact
|
|
- For queries relating to financial statement & investor matters |
Jill Deviprasad
Investor Relations
Biocon Corporate Headquarters
20th KM, Hosur Road,
Electronics City,
Bangalore,
Karnataka -
India
Pin
- 560 100 |
| Email: jill.deviprasad@biocon.com |
| Email: investor.relations@biocon.com |
| |
| - For compliance matters and for matters relating to shares/dividend: |
| Email: co.secretary@biocon.com |
| - Details of Registrar and Share Transfer Agents: |
| Email: mahender@karvy.com |
